Efficacy and safety of minocycline in patients with acute ischaemic stroke (EMPHASIS): a multicentre, double-blind, randomised controlled trial

2026/01/30 by Yao Lu, Ling Guan, Jialing Wu +22 · 2 voices
Medicine · Neuroscience · #Acute Ischemic Stroke Management #Neuroinflammation and Neurodegeneration Mechanisms #Neurological Disorders and Treatments

paper · doi:10.1016/s0140-6736(25)01862-8

openalex publication_date 2026/01/30 · crossref created 2026/01/30 · crossref issued 2026/02/01 · crossref published 2026/02/01 · crossref published-print 2026/02/01 · openalex created_date 2026/02/01 · crossref deposited 2026/04/29 · crossref indexed 2026/07/19 · openalex updated_date 2026/08/03

Citations

• Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.

Discussions

• 🔥EMPHASIS now on the Neurovascular Unit 🤔 🧠Neuroprotection ≠ neurons alone. 💊 Minocycline within 72 h of ischaemic stroke increased mRS 0–1 at 90 days (52.6% vs 47.4%; adjusted RR 1.11, 95% CI 1.0 [bsky, 0 points, 0 comments]
• Could an old tetracycline help stroke recovery? 🧠💊 In the EMPHASIS RCT, minocycline within 72h of acute ischemic stroke increased 90-day “excellent” outcomes (mRS 0–1) vs placebo. Stewardship questi [bsky, 0 points, 0 comments]